N-benzyloxycarbonyl-3,6-dideoxy-3,6-imino-1,2-O-isopropylidene-α-D-glucofuranose | 84730-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyloxycarbonyl-3,6-dideoxy-3,6-imino-1,2-O-isopropylidene-α-D-glucofuranose
• 英文别名: 3,6-(benzyloxycarbonyl)imino-3,6-dideoxy-1,2-O-isopropylidene-β-L-idofuranose；benzyl (1S,2R,6R,8S,9R)-9-hydroxy-4,4-dimethyl-3,5,7-trioxa-11-azatricyclo[6.3.0.02,6]undecane-11-carboxylate
• CAS: 84730-21-2
• 化学式: C₁₇H₂₁NO₆
• 分子量: 335.357
• InChiKey: ODAHDKKMUPBBBP-XLWJZTARSA-N

物化性质

• 沸点：
  484.8±45.0 °C(Predicted)
• 密度：
  1.314±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-benzyloxycarbonyl-3,6-dideoxy-3,6-imino-1,2-O-isopropylidene-α-D-glucofuranose 在 palladium on activated charcoal 、 钯 吡啶 、 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 molecular sieve 、 氢气 、 sodium methylate 、 乙酰氯 、 pyridinium chlorochromate 、 三氟乙酸 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 乙腈 、 苯 为溶剂， 反应 153.5h， 生成 (1R,7S,8R)-7-(羟基甲基)-2,3,5,6,7,8-六氢-1H-吡咯里嗪-1-醇
  参考文献：
  名称：

  Synthesis of the necine base platynecine from glucose

  摘要：

  A synthesis of platynecine from an intermediate is described which has previously been used for the synthesis of the enantiomers of retronecine; the stereochemistry of the necine base is determined by the formation of a tricyclic amide intermediate.

  DOI：

  10.1016/s0040-4020(01)90508-3
• 作为产物：
  描述：

  5-O-benzoyl-3,6-(benzyloxycarbonyl)imino-3,6-dideoxy-1,2-O-isopropylidene-β-L-idofuranose 在 sodium methylate 作用下， 以90%的产率得到N-benzyloxycarbonyl-3,6-dideoxy-3,6-imino-1,2-O-isopropylidene-α-D-glucofuranose
  参考文献：
  名称：

  用氢化锂铝还原1,2; 5,6-二-O-异亚丙基-α-d-葡糖呋喃糖衍生物; 3,6-亚氨基衍生物的简便合成方法

  摘要：

  摘要在沸腾的1,4-二恶烷中用氢化铝锂处理3-酰氨基-或烷基亚氨基-3-脱氧-1,2; 5,6-二-O-异亚丙基-α-d-葡萄糖呋喃糖可得到不同寻常的产物，即3，6-N-烷基亚氨基-3，6-二氧-1,2-O-异亚丙基-α-d-葡糖呋喃糖或6-O-异丙基-1,2-O-异亚丙基-α-d-葡糖呋喃糖衍生物。通过该反应，制备了3，6-N-（苄氧基）亚氨基-3，6-二脱氧-1,2-O-异亚丙基-β-1-异呋喃糖，其是合成茴香霉素的关键中间体。

  DOI：

  10.1016/0008-6215(83)88284-6

文献信息

• [EN] CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CYSTEINE PROTEASE
  申请人：MEDIVIR AB

  公开号：WO2005066180A1

  公开（公告）日：2005-07-21

  A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is C1-C4 straight or branched chain, optionally fluorinated, alkyl; R4 is H; or R3 together with R4 and the adjoining backbone carbon defines: a spiro-C5-C7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4 alkyl or C1-C4 haloalkyl; or optionally bridged with a methylene group; or a C4-C6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(=O)2 ; where Ra is H, C1-C4 alkyl or CH3C(=O); R5 is independently selected from H or methyl; E is -C(=O)-, -S(=O)m-, -NR5S(=O)m-, -NR5C(=O)-, -OC(=O)-, R6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or hetorocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

  一个公式为(II)的化合物，其中R1和R2中的一个是卤素，另一个是H或卤素；R3是C1-C4直链或支链，可选择氟代的烷基；R4是H；或者R3与R4和相邻的骨架碳一起定义：一个螺环C5-C7环烷基，可选地用1至3个卤素、羟基、C1-C4烷基或C1-C4卤代烷基中的取代基取代；或者可选地用亚甲基桥接；或者是一个具有O、NRa、S、S(=O)2等异原子的C4-C6饱和杂环；其中Ra是H、C1-C4烷基或CH3C(=O)；R5独立地选择自H或甲基；E是-C(=O)-、-S(=O)m-、-NR5S(=O)m-、-NR5C(=O)-、-OC(=O)-；R6是稳定的、可选择取代的、单环或双环的、碳环或杂环；m独立地为0、1或2；是猫hepsin K的抑制剂，并且在骨质疏松症的治疗或预防中有用。
• Cysteine Protease Inhibitors
  申请人：Tickle David

  公开号：US20090023747A1

  公开（公告）日：2009-01-22

  A compound of the formula (II) wherein one of R 1 and R 2 is halo and the other is H or halo; R 3 is —C 1 -C 5 straight or branched chain, optionally fluorinated, alkyl or —CH 2 CR 5 C 3 -C 4 -Cycloalkyl; R 4 is H; R 5 is H, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, hydroxyl, OC 1 -C 2 alkyl, fluoro; R 6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or heterocycle wherein the or each ring has 4, 5 or 6 ring atoms and 0 to 3 hetero atoms selected from S, O and N; Rb is haloalkyl; Rc is H or C 1 -C 4 alkyl; and pharmaceutically acceptable salts, hydrates or N-oxides thereof have utility in the treatment of disorders characterised by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

  化合物的公式（II），其中R1和R2中的一个是卤素，另一个是氢或卤素; R3是直链或支链，可选择氟化的C1-C5烷基或-CH2CR5C3-C4环烷基; R4是氢; R5是氢，C1-C2烷基，C1-C2卤代烷基，羟基，OC1-C2烷基，氟; R6是稳定的，可选地取代的单环或双环，碳环或杂环，其中每个环具有4、5或6个环原子和0到3个从S、O和N中选择的杂原子; Rb是卤代烷基; Rc是氢或C1-C4烷基;以及其药学上可接受的盐，水合物或N-氧化物在治疗由于cathepsin K不适当的表达或激活而表现出来的疾病中具有用途，如骨质疏松症、骨关节炎、类风湿性关节炎或骨转移。
• Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors
  申请人：Quibell Martin

  公开号：US20100010009A1

  公开（公告）日：2010-01-14

  The present invention relates to compounds of formula (1), and pharmaceutically acceptable salts thereof, A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof (I), wherein: one of R 1 and R 2 is H, and the other is selected from F and Cl, or R 1 and R 2 are both F; R 3 is selected from cyclopentyl and cyclohexyl; R 4 is an optionally substituted 5- or 6-membered monocyclic or an 8- to 10-membered bicyclic aryl or heteroaryl ring which includes up to four heteroatoms. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及式（1）的化合物及其药学上可接受的盐，式（I）的化合物或药学上可接受的盐、水合物、配合物或前药，其中：R1和R2中的一个为H，另一个为F和Cl中的一种，或R1和R2均为F；R3选自环戊基和环己基；R4为可选取代的5-或6-成员单环或8-到10-成员的双环芳基或杂环芳基环，其中包含最多四个杂原子。本发明还涉及包括式（I）的化合物的制药组合物，并且在治疗骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌疾病如骨转移和相关疼痛中使用这种化合物的用途。
• Cysteine Protease inhibitors
  申请人：Nilsson Magnus

  公开号：US20080234260A1

  公开（公告）日：2008-09-25

  A compound of the formula II wherein one of R 1 and R 2 is halo and the other is H or halo; R 3 is C 1 -C 4 straight or branched chain, optionally fluorinated, alkyl; R 4 is H; or R 3 together with R 4 and the adjoining backbone carbon defines: a spiro-C 5 -C 7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl; or optionally bridged with a methylene group; or a C 4 -C 6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(═O) 2 ; where Ra is H, C 1 -C 4 alkyl or CH 3 C(═O); R 5 is independently selected from H or methyl; E is —C(═O)—, —S(═O) m —, —NR 5 S(═O) m —, —NR 5 C(═O)—, —OC(═O)—, R 6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or heterocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

  化合物II的公式为其中R1和R2中的一个是卤素，另一个是氢或卤素;R3是C1-C4直链或支链，可选择氟代的烷基;R4是氢;或R3与R4和相邻的骨架碳一起定义:一个螺旋C5-C7环烷基，可选地被1至3个取代基所取代，所述取代基选自卤素、羟基、C1-C4烷基或C1-C4卤代烷基;或者可选地通过亚甲基基桥接;或者是一个C4-C6饱和杂环，其中杂原子选自O、NRa、S、S(═O)2;其中Ra是H、C1-C4烷基或CH3C(═O);R5是独立选择的H或甲基;E是—C(═O)—、—S(═O)m—、—NR5S(═O)m—、—NR5C(═O)—、—OC(═O)—;R6是稳定的、可选地取代的、单环或双环、碳环或杂环;m独立地为0、1或2;是猫hepsin K的抑制剂，用于治疗或预防骨质疏松症。
• PROTEASE INHIBITORS
  申请人：MEDIVIR AB

  公开号：US20130231349A1

  公开（公告）日：2013-09-05

  Compounds of the formula II: wherein R 1 and R 2 are independently H, F or CH 3 ; or R 1 forms an ethynyl bond and R 2 is H or C 3 -C 6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF 3 , OMe or halo; R 3 is C 1 -C 3 alkyl or C 3 -C 6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R 3 is C 3 -C 6 cycloalkyl it may alternatively be gem substituted with fluoro; R 4 is methyl or fluoro; m is 0, 1 or 2; E is a bond, or thiazolyl, optionally substituted with methyl or fluoro; A 1 is CH or N, A 2 is CR 6 R7 or NR 6 , provided at least one of A 1 and A 2 comprises N; R 6 is H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 3 alkyl-O—C 1 -C 3 alkyl, or when A 2 is C, R 6 can also be C 1 -C 4 alkoxy or F; R 7 is H, C 1 -C 4 alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

  化合物II的公式：其中，R1和R2独立地为H、F或CH3；或者R1形成一个乙炔键，而R2为H或C3-C6环烷基，该环烷基可选择性地被一个或两个取代基独立地选自甲基、CF3、OMe或卤素；R3为C1-C3烷基或C3-C6环烷基，其中任一种均可选择性地被一个或两个甲基和/或氟、三氟甲基或甲氧基取代，当R3为C3-C6环烷基时，它可以被氟原子取代；R4为甲基或氟；m为0、1或2；E为一个键，或噻唑基，该噻唑基可选择性地被甲基或氟取代；A1为CH或N，A2为CR6R7或NR6，其中至少一个为N；R6为H、C1-C4烷基、C1-C4卤代烷基、C1-C3烷基-O-C1-C3烷基，当A2为C时，R6也可以是C1-C4烷氧基或F；R7为H或C1-C4烷基。对于药学上可接受的盐、N-氧化物或其水合物，在治疗具有不适当表达或激活cathepsin K的疾病，如骨质疏松症、骨关节炎、类风湿性关节炎或骨转移方面具有用途。